Repatha 140 MG/ML sureclickml
Ended Awarded Last action
- Contract number
- SPE2DR26F8Y9R
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,370
Award facts
- Contract value 100% obligated
- $17,370.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $17,370.38 delivery order to AmerisourceBergen Drug Corp (Ultimate Unique Identifier: KABZK8W6PQT3) on January 12, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injectors. This is a firm fixed-price, non-set-aside contract with a completion date of January 13, 2026, and performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc. (doing business as AmerisourceBergen), a major pharmaceutical distributor and healthcare solutions provider serving federal military and veteran healthcare systems.
Repatha (evolocumab) is a PCSK9 inhibitor prescribed for cholesterol management in patients with cardiovascular disease or familial hypercholesterolemia, making this delivery order part of AmerisourceBergen's broader role as a critical pharmaceutical supplier to the Defense Health Agency and military treatment facilities. The company's extensive federal contract portfolio demonstrates its capacity to supply specialty medications, brand-name and generic pharmaceuticals, vaccines, and medical devices across multiple therapeutic domains through competitive award mechanisms. This delivery order reflects routine pharmaceutical procurement operations supporting military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26F8Y9R?
SPE2DR26F8Y9R was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26F8Y9R worth?
The government has obligated $17,370 on SPE2DR26F8Y9R.
Is contract SPE2DR26F8Y9R an order under another contract?
Yes. SPE2DR26F8Y9R is a delivery order under SPE2DR25D1107, an indefinite delivery contract.
Was contract SPE2DR26F8Y9R competed?
The extent of competition for SPE2DR26F8Y9R was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award